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Supplemental figure 1 
 
  
  
Supplemental Table 1. Sex-stratified analyses between hsCRP and cancer mortality in 5,526 participants (380 events) of the PREVEND study.  
Quartile 1 Quartile 2 P- value Quartile 3 P-value Quartile 4 P-value P for trend* 
Men         
Participants (n) 657 665  652  659 
  
Range, mgl/L <0.62 ≥0.62  ≥1.31  ≥2.84 
  
No. of deaths (%) 18 (2.7) 49 (7.4)  74 (11.3)  107 (16.2) 
  
Crude Ref. 2.74 [1.60-4.70] <0.001 4.45 [2.66-7.45] <0.001 6.68 [4.06-11.01] <0.001 <0.001 
Model 1 Ref. 1.85 [1.07-3.19] 0.027 2.50 [1.48-4.25] 0.001 3.11 [1.86-5.22] <0.001 <0.001 
Model 2 Ref. 1.89 [1.10-3.27] 0.022 2.55 [1.50-4.33] 0.001 3.11 [1.85-5.24] <0.001 <0.001 
Model 3 Ref. 1.90 [1.10-3.29] 0.021 2.57 [1.51-4.37] <0.001 3.06 [1.81-5.16] <0.001 <0.001 
Model 4 Ref. 1.90 [1.10-3.29] 0.022 2.54 [1.49-4.33] 0.001 3.01 [1.78-5.10] <0.001 <0.001 
Model 5 Ref. 1.93 [1.11-3.34] 0.019 2.55 [1.50-4.35] 0.001 2.98 [1.76-5.06] <0.001 <0.001 
Model 6 Ref. 1.86 [1.07-3.22] 0.028 2.37 [1.38-4.08] 0.002 2.57 [1.46-4.53] 0.001 0.019 
         
Women         
Participants (n) 727 719  722  725   
Range, mg/L <0.63 ≥0.63  ≥1.41  ≥3.25   
No. of deaths (%) 21 (2.9) 32 (4.5)  41 (5.7)  38 (5.2)   
Crude Ref. 1.52 [0.88-2.63] 0.14 1.95 [1.15-3.30] 0.013 1.84 [1.08-3.13] 0.025 0.08 
Model 1 Ref. 1.02 [0.58-1.79] 0.95 1.13 [0.65-1.98] 0.66 1.09 [0.61-1.95] 0.78 0.82 
Model 2 Ref. 1.04 [0.59-1.83] 0.89 1.09 [0.62-1.90] 0.76 1.07 [0.59-1.92] 0.83 0.90 
Model 3 Ref. 1.09 [0.62-1.93] 0.77 1.15 [0.65-2.05] 0.63 1.12 [0.61-2.05] 0.71 0.85 
Model 4 Ref. 1.04 [0.59-1.85] 0.89 1.12 [0.63-2.00] 0.70 1.07 [0.59-1.96] 0.82 0.91 
Model 5 Ref. 1.04 [0.59-1.86] 0.86 1.12 [0.62-2.00] 0.71 1.08 [0.58-1.98] 0.82 0.90 
Model 6 Ref. 1.01 [0.57-1.81] 0.96 1.06 [0.58-1.92] 0.86 0.95 [0.481.90] 0.88 0.77 
Hazard ratios were derived from Cox proportional hazards regression models.  
Model 1: crude model + age, sex, BMI, alcohol intake (<10g/d or >10 g/d) and smoking status (never, former current). 
Model 2: model 1 + diabetes, systolic blood pressure, lipid lowering drugs and anti-hypertensive medications. 
Model 3: model 2 + total cholesterol, HDL cholesterol and triglycerides. 
Model 4: Model 3 + history of CVD and history of cancer. 
Model 5: Model 4 + eGFRcreatinine cystatin C and UAE. 
Model 6: Model 5 + GlycA  
Triglycerides, UAE and hsCRP were log transformed when used as a continuous variable in the analyses.  
*Tests of trend across increasing quartiles were conducted by assigning the median for each quartile as its value and treating this as a continuous variable. 
Abbreviations: BMI, body mass index; HDL-cholesterol, high density lipoprotein cholesterol; CVD, cardiovascular disease; hsCRP, high–sensitivity C-reactive 
protein; UAE, urinary albumin excretion; PREVEND, Prevention of REnal and Vascular ENd-stage Disease.  
  
Supplemental Table 2. Sex-stratified analyses between GlycA and cancer mortality in 5,526 participants (380 events) of the PREVEND study. 
 
Quartile 1 Quartile 2 P- value Quartile 3 P-value Quartile 4 P-value P for trend* 
Men         
Participants (n) 655 644  667  667 
  
Range, µmol/L <305 ≥305  ≥338  ≥381 
  
No. of deaths (%) 30 (4.6) 47 (7.3)  70 (10.5)  101 (15.1) 
  
Crude Ref. 1.64 [1.04-2.60] 0.034 2.41 [1.57-3.70] <0.001 3.72 [2.48-5.59] <0.001 <0.001 
Model 1 Ref. 1.04 [0.65-1.66] 0.19 1.34 [0.86-2.06] 0.19 1.82 [1.19-2.79] 0.006 <0.001 
Model 2 Ref. 1.02 [0.64-1.63] 0.94 1.32 [0.85-2.05] 0.21 1.78 [1.16-2.74] 0.009 <0.001 
Model 3 Ref. 1.06 [0.66-1.70] 0.81 1.37 [0.87-2.13] 0.17 1.87 [1.20-2.90] 0.006 <0.001 
Model 4 Ref. 1.07 [.67-1.72] 0.78 1.36 [0.87-2.12] 0.18 1.84 [1.18-2.87] 0.007 0.001 
Model 5 Ref. 1.08 [0.67-1.73] 0.76 1.35 [0.86-2.11] 0.19 1.82 [1.16-2.84] 0.009 0.001 
Model 6 Ref. 0.99 [0.62-1.60] 0.98 1.14 [0.71-1.81] 0.59 1.35 [0.82-2.22] 0.24 0.12 
         
Women         
Participants (n) 712 715  743  723   
Range, µmol/L <313 ≥313  ≥352  ≥394   
No. of deaths (%) 18 (2.5) 27 (3.8)  45 (6.1)  42 (5.8)   
Crude Ref. 1.49 [0.82-2.70] 0.19 2.43 [1.41-4.20] 0.001 2.35 [1.35-4.07] 0.002 0.001 
Model 1 Ref. 1.06 [0.58-1.94] 0.86 1.49 [0.84-2.64] 0.17 1.38 [0.76-2.49] 0.29 0.20 
Model 2 Ref. 1.05 [0.57-1.92] 0.88 1.39 [0.78-2.47] 0.26 1.29 [0.71-2.34] 0.41 0.33 
Model 3 Ref. 1.09 [0.59-2.00] 0.79 1.40 [0.78-2.52] 0.27 1.36 [0.74-2.52] 0.32 0.27 
Model 4 Ref. 1.09 [0.59-2.00] 0.79 1.47 [0.81-2.64] 0.20 1.40 [0.76-2.58] 0.28 0.22 
Model 5 Ref. 1.10 [0.60-2.02] 0.77 1.47 [0.82-2.65] 0.20 1.41 [0.76-2.60] 0.27 0.22 
Model 6 Ref. 1.11 [0.60-2.06] 0.73 1.53 [0.83-2.81] 0.18 1.51 [0.76-3.01] 0.24 0.19 
Hazard ratios were derived from Cox proportional hazards regression models.  
Model 1: crude model + age, sex, BMI, alcohol intake (<10g/d or >10 g/d) and smoking status (never, former current). 
Model 2: model 1 + diabetes, systolic blood pressure, lipid lowering drugs and anti-hypertensive medications. 
Model 3: model 2 + total cholesterol, HDL cholesterol and triglycerides. 
Model 4: Model 3 + history of CVD and history of cancer. 
Model 5: Model 4 + eGFRcreatinine cystatin C and UAE. 
Model 6: Model 5 + hsCRP 
Triglycerides, UAE and hsCRP were log transformed when used as a continuous variable in the analyses.  
*Tests of trend across increasing quartiles were conducted by assigning the median for each quartile as its value and treating this as a continuous variable. 
Abbreviations: BMI, body mass index; HDL-cholesterol, high density lipoprotein cholesterol; CVD, cardiovascular disease; hsCRP, high–sensitivity C-reactive 
protein; UAE, urinary albumin excretion; PREVEND, Prevention of REnal and Vascular ENd-stage Disease.  
  
Supplemental Table 3. Association between GlycA and hsCRP levels and lung cancer mortality in 5,526 participants (57 events) of the PREVEND study.  
Per 1 SD increment P- value 
GlycA   
Crude 1.61 [1.33-1.95] <0.001 
Model 1 1.34 [1.07-1.67] 0.011 
Model 2 1.33 [1.06-1.67] 0.015 
Model 3 1.34 [1.07-1.67] 0.011 
Model 4 1.38 [1.02-1.88] 0.040 
hsCRP Per 1 SD increment  
Crude 1.48 [1.19-1.84] <0.001 
Model 1 1.18 [0.92-1.52] 0.19 
Model 2 1.17 [0.91-1.50] 0.23 
Model 3 1.18 [0.92-1.51] 0.19 
Model 4 0.96 [0.70-1.33] 0.81 
Hazard Ratios are given per 1 SD increment in GlycA and hsCRP 
Model 1: crude model + age, sex, BMI, alcohol intake (<10g/d or >10 g/d) and smoking status (never, former current). 
Model 2: model 1 + history of CVD and history of cancer. 
Model 3: model 2 + eGFRcreatinine cystatin C and UAE. 
Model 4: Model 3 + hsCRP (for GlycA analyses) + GlycA (for hsCRP analyses). 
UAE and hsCRP were log transformed when used as a continuous variable in the analyses.  
1 SD is 62 µmol/L for GlycA and 5.22 for hsCRP. Abbreviations: BMI, body mass index; CVD, cardiovascular disease; hsCRP, high–sensitivity C-reactive protein; 
UAE, urinary albumin excretion; PREVEND, Prevention of REnal and Vascular ENd-stage Disease.  
  
  
Supplemental Table 4. Association between GlycA and hsCRP levels and gastrointestinal cancer mortality in 5,526 participants (56 events) of the PREVEND 
study.  
Per 1 SD increment P- value 
GlycA   
Crude 1.31 [1.04-1.65] 0.023 
Model 1 1.39 [1.09-1.75] 0.007 
Model 2 1.40 [1.10-1.79] 0.007 
Model 3 1.42 [1.11-1.83] 0.006 
Model 4 1.41 [1.01-1.98] 0.043 
   
hsCRP   
Crude 1.22 [0.97-1.55] 0.094 
Model 1 1.25 [0.97-1.61] 0.08 
Model 2 1.24 [0.97-1.60] 0.09 
Model 3 1.25 [0.97-1.61] 0.08 
Model 4 1.01 [0.73-1.41] 0.95 
Hazard Ratios are given per 1 SD increment in GlycA and hsCRP 
The following organs belong to the category of gastrointestinal: bile duct, esophagus, colon + rectum, stomach, pancreas, small intestine and liver.  
Model 1: crude model + age, sex, BMI, alcohol intake (<10g/d or >10 g/d) and smoking status (never, former current). 
Model 2: model 1 + history of CVD and history of cancer. 
Model 3: model 2 + eGFRcreatinine cystatin C and UAE. 
Model 4: Model 3 + hsCRP (for GlycA analyses) + GlycA (for hsCRP analyses). 
UAE and hsCRP were log transformed when used as a continuous variable in the analyses.  
1 SD is 62 µmol/L for GlycA and 5.22 mg/L for hsCRP. Abbreviations: BMI, body mass index; CVD, cardiovascular disease; hsCRP, high–sensitivity C-reactive 
protein; UAE, urinary albumin excretion; PREVEND, Prevention of REnal and Vascular ENd-stage Disease.  
 
 
